Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

European Journal of Cancer ◽

10.1016/s0959-8049(16)30904-2 ◽

2015 ◽

Vol 51 ◽

pp. S318

Author(s):

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

H.A. Azim ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Lower Body ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

Subgroup Analyses ◽

Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability

Annals of Oncology ◽

10.1093/annonc/mdw364.67 ◽

2016 ◽

Vol 27 ◽

pp. vi63 ◽

Cited By ~ 1

Author(s):

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

X. Pivot ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Medical Conditions ◽

Her2 Positive ◽

Body Weights ◽

1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status

European Journal of Cancer ◽

10.1016/s0959-8049(16)30893-0 ◽

2015 ◽

Vol 51 ◽

pp. S313-S314

Author(s):

C. Jackisch ◽

R. Hegg ◽

D. Stroyakovskiy ◽

J.S. Ahn ◽

B. Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Phase Iii ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

63P Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients

Annals of Oncology ◽

10.1093/annonc/mdv519.12 ◽

2015 ◽

Vol 26 ◽

pp. ix16

Author(s):

M. Shing ◽

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Lower Body ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

55O_PR Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status

Annals of Oncology ◽

10.1093/annonc/mdv519.04 ◽

2015 ◽

Vol 26 ◽

pp. ix16 ◽

Cited By ~ 1

Author(s):

J.-S. Ahn ◽

C. Jackisch ◽

R. Hegg ◽

D. Stroyakovskiy ◽

B. Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Phase Iii ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.072 ◽

2018 ◽

Vol 93 ◽

pp. 19-27 ◽

Cited By ~ 29

Author(s):

X. Pivot ◽

I. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Reference Product ◽

Phase Iii ◽

Her2 Positive ◽

Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients

Annals of Oncology ◽

10.1093/annonc/mdy270.212 ◽

2018 ◽

Vol 29 ◽

pp. viii69

Author(s):

J. Cortes Castan ◽

M. Pegram ◽

X. Pivot ◽

G. Curigliano ◽

J.Y. Lim ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

Phase Iii ◽

Breast Cancer Patients ◽

Subgroup Analyses ◽

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.056 ◽

2021 ◽

Vol 32 ◽

pp. S37-S38

Author(s):

O. Metzger ◽

C. Lambertini ◽

I.E. Krop ◽

G. Lewis Phillips ◽

C.M. Perou ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Biomarker Analysis ◽

Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

Annals of Oncology ◽

10.1093/annonc/mdx362.003 ◽

2017 ◽

Vol 28 ◽

pp. v44-v45 ◽

Cited By ~ 3

Author(s):

F.J. Esteva ◽

Y. Baranau ◽

V. Baryash ◽

A. Manikhas ◽

V. Moiseyenko ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Double Blind ◽

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.800 ◽

2021 ◽

Author(s):

J. Huober ◽

C.H. Barrios ◽

N. Niikura ◽

M. Jarzab ◽

Y-C. Chang ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽